MV-140 is under clinical development by Inmunotek and currently in Phase III for Urinary Tract Infections. According to GlobalData, Phase III drugs for Urinary Tract Infections have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MV-140’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MV-140 (Uromune) is under development for the treatment of recurrent urinary tract infections (RUTI). MV-140 is a bacterial polyvalent vaccine composed of different proportions of whole heat-inactivated bacteria strains. The vaccine candidate is administered through sublingual route.
Inmunotek opearates as a pharmaceutical company. It develops, produces and markets products for allergy and other immune-based diseases and manufactures veterinary medicine. It also produces raw materials such as biological products, including fungi, bacteria and mites.
For a complete picture of MV-140’s drug-specific PTSR and LoA scores, buy the report here.